Atypical carcinoid tumour of the larynx

1995 ◽  
Vol 109 (5) ◽  
pp. 455-458 ◽  
Author(s):  
G. W. R. Watters ◽  
A. J. Molyneux
Keyword(s):  
Surgical Resection ◽  
Carcinoid Tumour ◽  
Primary Treatment ◽  
Referred Pain ◽  
Unusual Feature ◽  
Positive Staining ◽  
Atypical Carcinoid ◽  
Sustentacular Cells ◽  
S 100 ◽  
Diagnostic Difficulties

AbstractThe case of an atypical carcinoid tumour of the larynx is described in a 65-year-old man. Thisrare tumour may present diagnostic difficulties, but the diagnosis should be considered in a patient presenting with symptoms of local or referred pain and an apparently small, non-ulcerating supraglottic tumour. Immunocytochemistry has an important role in establishing the diagnosis. A very unusual feature of this case was positive staining for S-100 protein by sustentacular cells. Atypical carcinoid tumours do not respond well to radiotherapy so the primary treatment should be surgical resection.

Smooth muscle tumours of the larynx

1995 ◽  
Vol 109 (1) ◽  
pp. 77-79 ◽  
Author(s):  
D. C. McKiernan ◽  
G. W. R. Watters
Keyword(s):  
Smooth Muscle ◽  
Surgical Resection ◽  
Spindle Cell ◽  
Postoperative Radiotherapy ◽  
Squamous Carcinoma ◽  
Primary Treatment ◽  
Partial Laryngectomy ◽  
Malignant Tumours ◽  
Diagnostic Difficulties ◽  
Benign Leiomyoma

AbstractTwo cases of laryngeal smooth muscle tumours are reported: one a benign leiomyoma, the other a malignant leiomyosarcoma. These tumours may present diagnostic difficulties and immunocytochemistry is helpful in distinguishing smooth muscle tumours from other connective tissue neoplasms and spindle cell squamous carcinoma. Primary treatment in both cases should be surgical resection with small (T1, T2) malignant tumours suitable for partial laryngectomy. Postoperative radiotherapy may have a role in allowing a more limited surgical resection.

Endobronchial resection as a bridge to curative resection in patient with poor preoperative lung function secondary to an airway blocking endobronchial carcinoid tumour

2021 ◽  
pp. 201010582110507
Author(s):  
Muhammad Syafiek Mohd Razali ◽  
Muhammad Amin Ibrahim ◽  
Adli Azam Mohammad Razi ◽  
Mohammed Fauzi Abdul Rani
Keyword(s):  
Lung Function ◽  
Surgical Resection ◽  
Curative Resection ◽  
Surgical Planning ◽  
Carcinoid Tumour ◽  
Atypical Carcinoid ◽  
Precautionary Approach ◽  
Tumour Location ◽  
Predicted Values ◽  
Postoperative Lung Function

We present a 70-year-old gentleman with chronic cough with haemoptysis found to have left lower zone collapse on imaging. The bronchoscopy showed an endobronchial mass histologically of a non-secreting atypical carcinoid. Poor baseline lung function excluded surgical resection, and instead, he successfully underwent a bronchoscopic debulking procedure which improved his FEV1 to 84% and DLCO 83% predicted. Unfortunately, the tumour regrew, but the calculated percentage predicted postoperative for FEV1 (64%), and DLCO (65%) enabled definitive surgical resection to take place. Surgical resection remains the definite curative option for localised endobronchial atypical carcinoid tumours. Achieving this in proximal endobronchial carcinoid tumour is a challenge. We described an endoscopic tumour debulking procedure as a bridge for curative surgical resection in a patient with an inoperable proximal atypical carcinoid tumour due to poor predicted postoperative lung function. We highlighted the need to assess predicted postoperative lung function with functional and quantitative perfusion methods to aid surgical planning. Debulking the tumour by endoscopy can be used as a conduit to curative surgical resection in bronchial carcinoid tumour. The choice of calculating the percentage predicted values by either or both methods must be individualised based on tumour location and the probability of converting a lobectomy to a pneumonectomy. This precautionary approach could evaluate the postoperative lung function and morbidity and mortality risk if considering a pneumonectomy. Endoscopic debulking can be a successful bridge to a curative surgical resection aided by comprehensive preoperative lung function tests to predict postoperative lung values

AN ATYPICAL CARCINOID TUMOUR SECRETING 5-HYDROXYTRYPTOPHAN

The Lancet ◽  
1958 ◽  
Vol 271 (7012) ◽  
pp. 137-139 ◽  
Author(s):  
M. Sandler ◽  
P.J.D. Snow
Keyword(s):  
Carcinoid Tumour ◽  
Atypical Carcinoid

Cecal Mucosal Myxoma: The First Report of a New Type of Mesenchymal Colon Polyp

2019 ◽  
Vol 27 (6) ◽  
pp. 693-696
Author(s):  
Caroline Bsirini ◽  
Jennifer J. Findeis-Hosey ◽  
Aaron R. Huber
Keyword(s):  
Case Reports ◽  
Colonic Polyp ◽  
Screening Colonoscopy ◽  
Unknown Etiology ◽  
Positive Staining ◽  
Gi Tract ◽  
Sessile Polyp ◽  
First Case ◽  
S 100 ◽  
New Type

Myxomas are benign mesenchymal neoplasms of unknown etiology that most commonly occur in the cardiac atrium; however, other reported sites include the skin, joints, skeletal muscles, maxillofacial bones, and sinonasal tract. Myxomas involving the gastrointestinal (GI) tract are rare and are limited to a few published case reports. We are presenting, to our knowledge, the first case report of a mucosal myxoma in the colon presenting as a colonic polyp. A 49-year-old woman underwent a screening colonoscopy and was found to have a 0.2-cm sessile polyp in the cecum. Histologically, the polyp was composed of bland spindled cells in the lamina propria set in a hypocellular, myxoid stroma. The lesion was relatively well-demarcated from the surrounding mucosa. The overlying colonic epithelium showed no dysplasia. S-100 immunohistochemical stain showed only focal nonspecific positivity, while CD34, CD117, SMA, EMA, and desmin were all negative. Alcian blue special stain showed positive staining, supporting the diagnosis of myxoma. Myxomas in the GI tract are very rare, with this being the first reported case of a polypoid colonic mucosal myxoma. Previous reports of GI myxomas are limited to examples in the stomach, small bowel, and one recently reported case in the colon, all of which were submucosal lesions and not limited to the mucosa. In some of the prior reports, the patients had synchronous cardiac atrial myxomas. Mucosal colonic myxoma represents a newly identified mesenchymal polyp of the colon and pathologists should be aware of this diagnostic entity.

A randomized, double-blinded, placebo-controlled, multi-institutional, cross-over, phase II.5 study of saracatinib (AZD0530), a selective Src kinase inhibitor, in patients with recurrent osteosarcoma localized to the lung.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. TPS10591-TPS10591 ◽  
Author(s):  
Kristin Baird ◽  
Denise K. Reinke ◽  
Joseph Gerald Pressey ◽  
Leo Mascarenhas ◽  
Noah Federman ◽  
...  
Keyword(s):  
Surgical Resection ◽  
Phase Ii ◽  
Kinase Inhibitor ◽  
Treatment Guidelines ◽  
Src Kinase ◽  
Progression Free Survival ◽  
Primary Treatment ◽  
Complete Resection ◽  
Controlled Study ◽  
Complete Surgical Resection

TPS10591 Background: Osteosarcoma is a rare cancer and 33% of patients who have completed primary treatment will recur. The Src pathway has been implicated in the metastatic behavior of several tumors including osteosarcoma where 95% of samples express Src or have evidence of downstream activation of this pathway. Saracatinib (AZD0530) is a potent and selective Src kinase inhibitor. The recommended phase II dose in adults was found to be 175mg daily. The primary goal of this study is to determine if treatment with Saracatinib can increase progression free survival (PFS) for patients who have undergone complete resection of metastatic osteosarcoma nodules in the lung. Secondary goals are evaluation of overall survival, time to treatment failure, and evaluation of several biological correlatives. Methods: This is a multi-institutional, phase II.5, placebo-controlled study with an accrual goals of 88 randomized patients. Patients between 15 and 75 years, with histological confirmation of recurrent osteosarcoma, localized to the lung, who have potential for complete surgical resection, are eligible for enrollment. After complete resection, patients are randomized to treatment with saracatinib or placebo, of a daily oral dose of 175 mg, continuously for up to 1 year or until progression. Patients who recur in the lung while on-study and who are amenable to complete surgical resection will be un-blinded. Those patients who received placebo may have the option to undergo surgical resection. If fully resected, they will be offered therapy with saracatinib under the same treatment guidelines as above. As of January 2013, 38 patients have enrolled and 32 patients met the criteria to be randomized and began oral therapy with either saracatinib or placebo. An interim analysis is planned after 40 patients have been randomized. Clinical trial information: NCT00752206.

Recurrence of acoustic neurilemoma as a malignant spindle-cell neoplasm

1990 ◽  
Vol 73 (6) ◽  
pp. 946-950 ◽  
Author(s):  
Catriona A. McLean ◽  
John D. Laidlaw ◽  
David S. B. Brownbill ◽  
Michael F. Gonzales
Keyword(s):  
Cerebellopontine Angle ◽  
Spindle Cell ◽  
Positive Staining ◽  
Nerve Sheath Tumor ◽  
Content Type ◽  
Spindle Cell Neoplasm ◽  
Nerve Sheath ◽  
Cell Neoplasm ◽  
Acoustic Nerve ◽  
S 100

✓ A 75-year-old man presented with a right cerebellopontine angle tumor 11 months after complete macroscopic resection of a right acoustic neurilemoma. Histological examination of the recurrent tumor showed a malignant spindle-cell neoplasm with positive staining for S-100 protein. The patient had no stigmata of von Recklinghausen's disease. It is proposed that this recurrence represents progression from a benign to a malignant acoustic nerve-sheath tumor, an event that is extremely rare outside the clinicopathological context of neurofibromatosis.

Stereotactic Radiosurgery as the Primary Treatment for New and Recurrent Paragangliomas: Is Open Surgical Resection Still the Treatment of Choice?

2012 ◽  
Vol 77 (5-6) ◽  
pp. 745-761 ◽  
Author(s):  
Robert E. Lieberson ◽  
John R. Adler ◽  
Scott G. Soltys ◽  
Clara Choi ◽  
Iris C. Gibbs ◽  
...  
Keyword(s):  
Stereotactic Radiosurgery ◽  
Surgical Resection ◽  
Primary Treatment

Immunocytochemical evidence that S-100-positive cells of the mouse anterior pituitary contain interleukin-6 immunoreactivity.

1993 ◽  
Vol 41 (2) ◽  
pp. 151-156 ◽  
Author(s):  
H Vankelecom ◽  
P Matthys ◽  
J Van Damme ◽  
H Heremans ◽  
A Billiau ◽  
...  
Keyword(s):  
Interleukin 6 ◽  
Anterior Pituitary ◽  
Tumor Cell Line ◽  
Polyclonal Antiserum ◽  
Positive Staining ◽  
Pituitary Cells ◽  
S 100 ◽  
Mouse Pituitary ◽  
Acth Secreting

We have previously shown that bioactive interleukin-6 (IL-6) is produced by rat and mouse (anterior) pituitary cells in vitro. Since the amount produced correlated with the presence of S-100-containing folliculostellate (FS) cells, these cells were suggested to be a source of IL-6 in the anterior pituitary (AP) lobe. In the present study we used immunocytochemical techniques to confirm this presumption. Freshly isolated mouse pituitary cells were subjected to immunocytochemical procedures whereby two different (neutralizing) monoclonal antibodies (MAb) against mouse IL-6 (6B4 and 20F3) and a polyclonal antiserum raised against bovine S-100 were used as primary antibodies. Single immunostaining revealed a small portion of mouse pituitary cells (about 6.5%) to be positive for IL-6 immunoreactivity with both antibodies. Importantly, the same proportion of cells was found to be IL-6 positive if only the AP was used as the cell source. About 7.5% of the pituitary cells stained for the presence of S-100 immunoreactivity. Positive staining for IL-6 was also found in pituitary cell samples from 2-day-old monolayer cultures and from redispersed 9-day-old histotypic aggregates, which both secreted bioassayable IL-6. In contrast, no IL-6 staining was found in AtT-20 cells, an established ACTH-secreting tumor cell line of the mouse pituitary which did not secrete bioactive IL-6. The specificity of the IL-6 immunostaining was demonstrated by a total loss of staining when MAb 6B4 was omitted or replaced by irrelevant rat IgG. Conclusively, pre-adsorption of the anti-IL-6 MAb (6B4) with recombinant mouse IL-6 totally abolished staining of pituitary cells. Double immunostaining for IL-6 and S-100 revealed that most if not all of the IL-6-containing pituitary cells were positive for S-100. Few of the S-100-containing cells did not stain for IL-6. These results confirm our previous hypothesis that FS cells, characterized by immunostaining of S-100 protein, contain bioactive and immunoreactive IL-6 and therefore are very likely producers of IL-6 in the AP. Furthermore, our results suggest that IL-6 is implicated in the local regulatory role ascribed to FS cells in the pituitary gland.

Intracranial angiosarcoma arising from a schwannoma

2006 ◽  
Vol 121 (1) ◽  
pp. 68-71 ◽  
Author(s):  
T Ito ◽  
T Tsutsumi ◽  
K Ohno ◽  
T Takizawa ◽  
K Kitamura
Keyword(s):  
Surgical Resection ◽  
Vestibular Schwannoma ◽  
Histological Diagnosis ◽  
Review Of The Literature ◽  
First Report ◽  
Cd34 Antigen ◽  
S 100 ◽  
Base Of The Skull

Angiosarcomas rarely arise from schwannomas, but we describe here a case of angiosarcoma that arose from a remnant of a benign vestibular schwannoma that had been removed 10 years earlier. The patient was a 66-year-old man with no sign of neurofibromatosis. Although we attempted surgical resection, we could not totally remove the tumour. The patient died nine months after diagnosis, primarily as result of an abscess in the cerebellum and base of the skull. The histological diagnosis was confirmed by the immunohistochemical findings of positivity for CD34 antigen and S-100 protein in the resected tumour.A review of the literature revealed four other cases of angiosarcoma with schwannoma, all of which arose from an extracranial nerve. The present case is the first report of an angiosarcoma with schwannoma arising from an intracranial locus.

Sign in / Sign up

Export Citation Format

Share Document